NASDAQ: PSTV
Plus Therapeutics Inc Stock

$0.49+0.04 (+8.89%)
Updated Sep 5, 2025
PSTV Price
$0.49
Fair Value Price
N/A
Market Cap
$48.64M
52 Week Low
$0.16
52 Week High
$2.31
P/E
-0.24x
P/B
16.03x
P/S
3.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.32M
Earnings
-$19.03M
Gross Margin
100%
Operating Margin
-287.76%
Profit Margin
-357.9%
Debt to Equity
2.41
Operating Cash Flow
-$17M
Beta
0.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PSTV Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PSTV's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PSTV
Ranked
Unranked of 482

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important PSTV news, forecast changes, insider trades & much more!

PSTV News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PSTV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PSTV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PSTV is poor value based on its book value relative to its share price (16.03x), compared to the US Biotechnology industry average (4.72x)
P/B vs Industry Valuation
PSTV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PSTV due diligence checks available for Premium users.

Valuation

PSTV price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.24x
Industry
-122.34x
Market
35.5x

PSTV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
16.03x
Industry
4.72x
PSTV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PSTV's financial health

Profit margin

Revenue
$1.4M
Net Income
$5.2M
Profit Margin
370.6%
PSTV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PSTV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.4M
Liabilities
$7.3M
Debt to equity
2.41
PSTV's short-term assets ($9.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PSTV's short-term assets ($9.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PSTV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PSTV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.8M
Investing
-$4.6M
Financing
$2.8M
PSTV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PSTV vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PSTV$48.64M+8.89%-0.24x16.03x
TPSTD$48.80M+9.57%-0.75x4.99x
FGEND$48.93M+6.98%-31.84x-0.22x
VRCAC$48.22M-1.07%-0.66x-2.76x
ATNMD$49.29M-6.51%-1.07x1.92x

Plus Therapeutics Stock FAQ

What is Plus Therapeutics's quote symbol?

(NASDAQ: PSTV) Plus Therapeutics trades on the NASDAQ under the ticker symbol PSTV. Plus Therapeutics stock quotes can also be displayed as NASDAQ: PSTV.

If you're new to stock investing, here's how to buy Plus Therapeutics stock.

What is the 52 week high and low for Plus Therapeutics (NASDAQ: PSTV)?

(NASDAQ: PSTV) Plus Therapeutics's 52-week high was $2.31, and its 52-week low was $0.16. It is currently -78.79% from its 52-week high and 206.25% from its 52-week low.

How much is Plus Therapeutics stock worth today?

(NASDAQ: PSTV) Plus Therapeutics currently has 99,264,526 outstanding shares. With Plus Therapeutics stock trading at $0.49 per share, the total value of Plus Therapeutics stock (market capitalization) is $48.64M.

Plus Therapeutics stock was originally listed at a price of $1,320,554.12 in Nov 16, 2000. If you had invested in Plus Therapeutics stock at $1,320,554.12, your return over the last 24 years would have been -100%, for an annualized return of -46.04% (not including any dividends or dividend reinvestments).

How much is Plus Therapeutics's stock price per share?

(NASDAQ: PSTV) Plus Therapeutics stock price per share is $0.49 today (as of Sep 5, 2025).

What is Plus Therapeutics's Market Cap?

(NASDAQ: PSTV) Plus Therapeutics's market cap is $48.64M, as of Sep 6, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Plus Therapeutics's market cap is calculated by multiplying PSTV's current stock price of $0.49 by PSTV's total outstanding shares of 99,264,526.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.